Total population | No prior tocilizumab combination (n = 6821) | Ever prior tocilizumab combination (n = 448) | ||
---|---|---|---|---|
Baseline only | Baseline and follow-up | Baseline and follow-up | Baseline and follow-up | |
Age, per year | 0.99 (0.98, 1.00) | 1.04 (1.00, 1.08) | 1.03 (0.99, 1.07) | 1.03 (1.00, 1.06) |
Male vs. female | 0.82 (0.61, 1.11) | 0.72 (0.24, 2.19) | 1.01 (0.30, 3.37) | 0.67 (0.30, 1.53) |
Disease duration, per year | 0.99 (0.98, 1.01) | 1.04 (1.00, 1.07) | 1.04 (1.00, 1.08) | 1.05 (0.99, 1.10) |
Serologic status* | ||||
Negative | Reference | |||
Positive | 0.73 (0.57–0.93) | 2.82 (0.46, 17.2) | 0.38 (0.07, 2.18) | 1.36 (0.27, 6.69) |
Missing | 0.50 (0.29–0.84) | 9.58 (1.85, 49.7) | 1.72 (0.39, 7.67) | 0.99 (0.33, 3.03) |
DMARD use** | ||||
csDMARD, baseline | 0.48 (0.37–0.63) | – | – | – |
TCZ combination | – | 327 (80, 1343) | – | – |
TNFi | – | 0.21 (0.09, 0.49) | 0.28 (0.11, 0.73) | 0.08 (0.03, 0.21) |
nonTNFi nonTCZ bDMARD | – | 1.73 (0.86, 3.50) | 2.70 (1.25, 5.85) | 0.17 (0.07, 0.37) |
Only csDMARD | – | 0.94 (0.36, 2.47) | 1.16 (0.40, 3.39) | 2.76 (1.18, 6.47) |
No DMARDs | – | 0.05 (0.01, 0.16) | 0.09 (0.03, 0.33) | 0.02 (0, 0.12) |
Glucocorticoid use | – | 0.74 (0.39, 1.40) | 0.91 (0.46, 1.78) | 0.91 (0.46, 1.78) |
CDAI, severe | – | Reference | Reference | Reference |
Moderate | – | 0.43 (0.23, 0.78) | 0.41 (0.22, 0.79) | 0.44 (0.17, 1.17) |
Low | – | 0.39 (0.21, 0.74) | 0.40 (0.20, 0.79) | 0.70 (0.29, 1.70) |
Remission | – | 0.17 (0.07, 0.42) | 0.11 (0.04, 0.32) | 0.53 (0.18, 1.52) |
Comorbidities, count# | – | 1.04 (0.98, 1.11) | 1.09 (1.01, 1.18) | 1.01 (0.92, 1.11) |